IMNM

Immunome Inc

IMNM, USA

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

https://immunome.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
IMNM
stock
IMNM

Immunome (IMNM) Is Up 15.3% After Desmoid Tumor Phase 3 Win and NDA Timeline Update – Has The Bull Case Changed? simplywall.st

Read more →
IMNM
stock
IMNM

Why Immunome Stock Surged Today Finviz

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$24.7273

Analyst Picks

Strong Buy

7

Buy

2

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

6.52

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-21.77 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-19.19 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.13

Low 1

High 0.3

Investors

* Institutions hold a combined 113.76% of the total shares of Immunome Inc

1.

T. Rowe Price Investment Management,Inc.

(9.5069%)

since

2025/06/30

2.

FMR Inc

(7.0856%)

since

2025/06/30

3.

BlackRock Inc

(6.6295%)

since

2025/06/30

4.

Redmile Group, LLC

(5.5974%)

since

2025/06/30

5.

Enavate Sciences GP, LLC

(5.4783%)

since

2025/06/30

6.

Point72 Asset Management, L.P.

(5.3832%)

since

2025/06/30

7.

Vanguard Group Inc

(5.1984%)

since

2025/06/30

8.

EcoR1 Capital, LLC

(4.6866%)

since

2025/06/30

9.

Opaleye Management Inc

(4.0549%)

since

2025/06/30

10.

Fidelity Growth Compy Commingled Pl S

(3.8974%)

since

2025/07/31

11.

T. Rowe Price Small-Cap Stock

(3.5828%)

since

2025/07/31

12.

T. Rowe Price US Small-Cap Core Equity

(3.4861%)

since

2025/06/30

13.

PRIMECAP Management Company

(3.4697%)

since

2025/06/30

14.

T. Rowe Price Associates, Inc.

(3.4259%)

since

2025/06/30

15.

PRIMECAP Odyssey Aggressive Growth

(3.0742%)

since

2025/06/30

16.

State Street Corp

(2.8961%)

since

2025/06/30

17.

Fidelity Growth Company Fund

(2.7374%)

since

2025/07/31

18.

Vanguard Total Stock Mkt Idx Inv

(2.5203%)

since

2025/07/31

19.

T. Rowe Price Health Sciences

(2.4844%)

since

2025/07/31

20.

The Toronto-Dominion Bank

(2.3961%)

since

2025/06/30

21.

Jefferies Financial Group Inc

(2.3961%)

since

2025/06/30

22.

Geode Capital Management, LLC

(2.1375%)

since

2025/06/30

23.

iShares Russell 2000 ETF

(2.0459%)

since

2025/08/31

24.

Woodline Partners LP

(1.9055%)

since

2025/06/30

25.

T. Rowe Price Instl Small-Cap Stock

(1.8083%)

since

2025/07/31

26.

T. Rowe Price U.S. SC Core Eq Tr-D

(1.7067%)

since

2025/06/30

27.

Readystate Asset Management LP

(1.555%)

since

2025/06/30

28.

Marshall Wace Asset Management Ltd

(1.4909%)

since

2025/06/30

29.

HHG PLC

(1.1953%)

since

2025/06/30

30.

Polar Capital Holdings PLC

(1.1488%)

since

2025/06/30

31.

Polar Capital Biotech S Inc

(1.1488%)

since

2025/07/31

32.

SPDR® S&P Biotech ETF

(1.0694%)

since

2025/08/31

33.

T. Rowe Price Small-Cap Value

(1.0601%)

since

2025/07/31

34.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0124%)

since

2025/07/31

35.

Fidelity Small Cap Index

(0.8499%)

since

2025/06/30

36.

Fidelity Growth Company K6

(0.8404%)

since

2025/07/31

37.

Fidelity Series Growth Company

(0.7716%)

since

2025/07/31

38.

iShares Russell 2000 Growth ETF

(0.7373%)

since

2025/08/31

39.

Fidelity Select Biotechnology

(0.6715%)

since

2025/07/31

40.

T. Rowe Price U.S. SC Value Eq Tr-D

(0.6163%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.5399

Latest Release

Date

2025-09-30

EPS Actual

-0.65

EPS Estimate

-0.567

EPS Difference

-0.083

Surprise Percent

-14.6384%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.